Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 10
First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient
Panelists discuss how their clinical experience with ESA failure rates and timelines compares with reported outcomes in large community practice studies, and how they counsel patients on the choice between luspatercept and ESAs as first-line therapy for lower-risk MDS, incorporating patient preferences and patient-reported outcomes from recent clinical trials.
Video content above is prompted by the following:
- Please describe: In your clinical practice, what percentage of your patients have disease that fails ESA? What is the general time frame where you may see ESA failure?
- How does this compare with reported ESA outcomes? Resource link: Gordan L, et al. LR-MDS large US community practice: pt outcomes post ESA Tx. EHA 2024 abstract.
- Please describe what you typically counsel and/or share with your patients when considering luspatercept vs ESA as first-line therapy for LR-MDS. How do you take into consideration the patient’s preference
Resource link: Olivia EN, et al. Patient-reported outcomes from COMMANDS study. ASH 2023 abstract.
Related Content:
